newsfilter
← Latest News
GlobeNewswire·

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights

– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA.